Table 3. Relative risk of novel doublet... | American Society of Hematology

Table 3.

Relative risk of novel doublet and triplet combinations in relapsed MM

Combination	HR for PFS	PFS (mo)	≥VGPR, %	≥CR, %	Remarks
Elotuzumab-Rd vs Rd	0.71	19	35	5	Effective after 2-3 lines of therapy
Carfilzomib-Rd vs Rd	0.69	26.3	38	32	Effective after 1 line
Daratumumab-Rd vs Rd	0.37	NR at 18 mo	76	43	Most effective in high-risk cytogenetics
Ixazomib-Rd vs Rd	0.82	20.6	48	32	Effective after 2−3 lines
Daratumumab-Vd vs Vd	0.39	NR at 12 mo	28	10	More effective than carfilzomib-dexamethasone
Panobinostat-Vd vs Vd	0.63	12	28	11	Available for ≥3 lines
Carfilzomib-d vs bortezomib-d	0.53	18.3	54	13	More affordable, less toxic

Combination	HR for PFS	PFS (mo)	≥VGPR, %	≥CR, %	Remarks
Elotuzumab-Rd vs Rd	0.71	19	35	5	Effective after 2-3 lines of therapy
Carfilzomib-Rd vs Rd	0.69	26.3	38	32	Effective after 1 line
Daratumumab-Rd vs Rd	0.37	NR at 18 mo	76	43	Most effective in high-risk cytogenetics
Ixazomib-Rd vs Rd	0.82	20.6	48	32	Effective after 2−3 lines
Daratumumab-Vd vs Vd	0.39	NR at 12 mo	28	10	More effective than carfilzomib-dexamethasone
Panobinostat-Vd vs Vd	0.63	12	28	11	Available for ≥3 lines
Carfilzomib-d vs bortezomib-d	0.53	18.3	54	13	More affordable, less toxic

d, dexamethasone; NR, not reached.